Gyala Therapeutics is conducting a Phase I/IIa clinical trial to evaluate the safety of GYA01, an investigational CD84-targeted CAR-T cell therapy, in patients with relapsed or refractory acute myeloid leukemia (AML) and acute lymphoblastic T leukemia (T-ALL).
The study enrolls patients with limited or no remaining therapeutic options and is being conducted at two reference hematology centers in Spain: Hospital La Fe in Valencia and Hospital Clínic Barcelona.
For complete and authoritative information on study design, eligibility criteria, recruitment status, and site-specific contacts, please consult the official clinical trial registries:
Spanish Clinical Trials Registry (REec): https://reec.aemps.es/reec/estudio/2024-519966-31-00
Contact
For general corporate or study-related information only:
Gyala Therapeutics, SL
info@gyalatx.com / +34 684 765 219
Please do not include personal health information or identifiable patient data in your message. Gyala Therapeutics does not assess patient eligibility, provide medical advice, or enrol patients directly. Participation decisions are made exclusively by the participating clinical centres.
Messages sent to this email address are reviewed only for general enquiries; any health information provided will not be used to assess eligibility and may be deleted or blocked in accordance with applicable legal obligations.
If you are a potential patient, please contact the clinical sites using the details published in the registries above.